The listing marks a potentially triumphant comeback story and an insult of sorts to the embattled London stock exchange.

Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day. The company, ...

(NEO) stock saw a modest uptick, ending the day at $14.71 which represents a slight increase of $0.93 or 6.75% from the prior close of $13.78. The stock opened at $14.95 and touched a low of $14.48 ...

In Trump versus the rest of the world, Trump is the indescribable enigma. The rest are demystified and stranded.

Uranium developer Neo Energy Metals has appointed investment and merchant banking boutique Bacchus Capital Advisers as its strategic and financial adviser. Bacchus Capital specialises in strategic and ...

NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...